- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Metformin therapy significantly lowers incidence of long Covid
A randomized phase 3 study from the Cold Spring Harbor Laboratory found that the incidence of Long Covid was 42% lower in the metformin group than in the blinded control group.
Long Covid is a new chronic condition that might impact millions of people and occasionally make it impossible for them to work or engage in regular daily activities. This research, COVID-OUT, was a phase 3, quadruple-blinded, placebo-controlled, investigator-initiated, randomized, multi-site clinical investigation. To effectively share placebo controls, the design evaluated three oral medications (metformin, fluvoxamine, and ivermectin) at the same time. Long Covid outcomes were monitored for 10 months to determine whether early outpatient treatment of SARS-CoV-2 with ivermectin, metformin, or fluvoxamine prevents Long Covid.
In the US, 1,125 persons aged 30 to 85 who were overweight or obese, had less than seven days' worth of symptoms, and had signed up within three days of having a confirmed SARS-CoV-2 infection participated in this decentralized, remotely administered experiment. Fluvoxamine, 50 mg on day one and 50 mg twice a day for 14 days. Immediate release metformin, titrated over 6 days to 1,500 mg per day for a total of 14 days. A predetermined secondary objective was the participant reporting a medical provider's diagnosis of Long Covid by day 300 following randomization; the trial's primary outcome was severe Covid by day 14.
The key findings of this study were:
1.45 years old on average, 56% female, and 7% pregnant. Native Americans made up 2% of the population, followed by Asians at 3.7%, Black/African Americans at 7.4%, Whites at 82.8%, and Hispanics at 12.7%.
2.The average BMI was 29.8 kg/m2, and 51% had a BMI more than 30 kg/m2.
3.Overall, 6.3% of those on metformin and 10.6% of those taking a metformin control, 8.0% of those taking ivermectin and 8.1% of those taking a fluvoxamine control, and 10.1% of those taking a fluvoxamine control reported receiving a diagnosis of Long Covid from a medical professional.
4.The Hazard Ratio (HR) for Long Covid was 0.58 for the metformin group, 0.99 for the ivermectin group, and 1.36 for the fluvoxamine group when compared to the control group.
Reference:
Bramante, C. T., Buse, J. B., Liebovitz, D., Nicklas, J., Puskarich, M. A., Cohen, K., Belani, H., Anderson, B., Huling, J. D., Tignanelli, C., Thompson, J., Lindberg, S., Wirtz, E. L., … Boulware, D. R. (2022). Outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine and the development of Long Covid over 10-month follow-up. Cold Spring Harbor Laboratory. https://doi.org/10.1101/2022.12.21.22283753
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751